Trial Selection Rising

NTRK fusion

NSCLC · Immune Checkpoint Inhibitor

NTRK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 5

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 5

Common snippets: MET exon 14 skipping | KRAS G12C | KRAS G12C

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: High

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT06364917 | https://clinicaltrials.gov/study/NCT07111520 | https://clinicaltrials.gov/study/NCT07285434 | https://clinicaltrials.gov/study/NCT06119581 | https://clinicaltrials.gov/study/NCT06711900